Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - natalizumabum - concentrato per soluzione per infusione - natalizumabum 300 mg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas heptahydricus, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 15 ml corresp. natrium 52 mg. - multiple sklerose - biotechnologika

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited  - siponimod acido fumarico - sclerosi multipla recidivante-remittente - immunosoppressori selettivi - mayzent è indicato per il trattamento di pazienti adulti con sclerosi multipla secondaria progressiva (spm) con malattia attiva evidenziata da recidive o funzioni di imaging di attività infiammatoria.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - ozanimodum - capsule rigide - ozanimodum 0.23 mg ut ozanimodi hydrochloridum 0.25 mg, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 0.187 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172, drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172, pro capsula. - multiple sklerose, colitis ulcerosa - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - ozanimodum - capsule rigide - ozanimodum 0.46 mg ut ozanimodi hydrochloridum 0.5 mg, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 0.187 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172, drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172, pro capsula. - multiple sklerose, colitis ulcerosa - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - ozanimodum - capsule rigide - ozanimodum 0.92 mg ut ozanimodi hydrochloridum 1, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 0.187 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172, drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172, pro capsula. - multiple sklerose, colitis ulcerosa - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetilfumarato - sclerosi multipla recidivante-remittente - immunosoppressori - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Unione Europea - italiano - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - sclerosi multipla - immunosoppressori selettivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Unione Europea - italiano - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - sclerosi multipla recidivante-remittente - immunosoppressori - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - sclerosi multipla recidivante-remittente - immunosoppressori selettivi immunosoppressori - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

teva b.v. - teriflunomide - teriflunomide